glp 1 gip gcg GLP-1R, GIPR, and GCGR: Targets for Obesity and Diabetes The Clinical Application of GLP-1RAs

In addition, the GLP-1 can inhibit postprandial gastric emptying and reduce gastric acid secretion, inhibit gastric and duodenal peristalsis by inhibiting vagus nerve, and increase the pressure of pylorus, thus reducing appetite, causing a reduction in body weight and participating in the so-called ileal braking effect (35)

For weight loss, other options include Saxenda (liraglitude) and Zepbound (tirzepatide)

Interleukin-6 predicts inflammation-induced increase of glucagon-like peptide-1 in humans in response to cardiac surgery with association to parameters of glucose metabolism

doi: 10.1210/endo-101-2-635

GLP-1 medications, bariatric surgery, peptide therapy, and other medical weight loss treatments require evaluation by a licensed healthcare provider

On the other hand, it was demonstrated that chronic stress in laboratory animals can shift the microbial diversity in the gastrointestinal tract [102, 103]